参考文献/References:
［1］ 王宁,刘硕,杨雷,等.2018全球癌症统计报告解读［J］.肿瘤综合治疗电子杂志,2019,5(1):87-97.DOI:10.12151/JMCM.2019.01-10.
［2］ ZHI X Y,ZOU X N,HU M,et al.Increased lung cancer mortality rates in the Chinese population from 1973-1975 to 2004-2005:an adverse health effect from exposure to smoking［J］.Cancer,2015,121 （Suppl 17）:3107-3112.
［3］ PLANCHARD D，POPAT S，KERR K，et al．Metastatic non-small cell lung cancer:ESMO clinical practice guidelines for diagnosis，treatment and follow-up［J］．Ann Oncol，2019，30(Suppl 4):iv192-iv237.
［4］ JAHCHAN N S,LIM J S,BOLA B,et al.Identification and targeting of long-term tumor-propagating cells in small cell lung cancer［J］.Cell Rep,2016,16(3):644-656.
［5］ WOOD D E,KAZEROONI E A,BAUM S L,et al.Lung cancer screening,version 3.2018,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2018,16(4):412-441.
［6］ VARGHESE A M,ZAKOWSKI M F,YU H A,et al.Small-cell lung cancers in patients who never smoked cigarettes［J］.J Thorac Oncol,2014,9(6):892-896.
［7］ XIE C,WAN X,QUAN H,et al.Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor［J］.Cancer Sci,2018,109(4):1207-1219.
［8］ TAURIN S,YANG C H,REYES M,et al.Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model［J］.Int J Gynecol Cancer,2018,28(1):152-160.
［9］ SYED Y Y.Anlotinib:first global approval［J］.Drugs,2018,78(10):1057-1062.
［10］ 中国医师协会肿瘤医师分会,中国临床肿瘤学会血管靶向治疗专家委员会,中国抗癌协会肿瘤靶向治疗专业委员会.盐酸安罗替尼治疗晚期肺癌中国专家共识(2020版)［J］.中华肿瘤杂志,2020,42(10):807-816.
［11］ LIANG L,HUI K,HU C,et al.Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells［J］.J Exp Clin Cancer Res,2019,38(1):71.
［12］ HU H,LIU Y,TAN S,et al.Anlotinib exerts anti-cancer effects on KRAS-mutated lung cancer cell through suppressing the MEK/ERK pathway［J］.Cancer Manag Res,2020,12:3579-3587.
［13］ TANG X,ZHENG Y,JIAO D,et al.Anlotinib inhibits cell proli-feration,migration and invasion via suppression of c-Met pathway and activation of ERK1/2 pathway in H446 cells［J］.Anticancer Agents Med Chem,2021,21(6):747-755.
［14］ COCHRANE D R,SPOELSTRA N S,HOWE E N,et al.Micro-RNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents［J］.Mol Cancer Ther,2009,8(5):1055-1066.
［15］ MA D B,QIN M M,SHI L,et al.MicroRNA-6077 enhances the sensitivity of patients-derived lung adenocarcinoma cells to anlotinib by repressing the activation of glucose transporter 1 pathway［J］.Cell Signal,2019,64:109391.
［16］ LIAN Z,DU W,ZHANG Y,et al.Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation［J］.Thorac Cancer,2020,11(7):1934-1943.
［17］ LU J,XU W,QIAN J,et al.Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells［J］.BMC Med Genomics,2019,12(Suppl 2):38.
［18］ LU J,SHI Q,ZHANG L,et al.Integrated transcriptome analysis reveals KLK5 and L1CAM predict response to anlotinib in NSCLC at 3rd line［J］.Front Oncol,2019,9:886.
［19］ LU J,ZHONG H,CHU T,et al.Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy［J］.Eur Respir J,2019,53(3):1801562.
［20］ LIU Z,WANG J,MENG Z,et al.CD31-labeled circulating endothelial cells as predictor in anlotinib-treated non-small-cell lung cancer:analysis on ALTER-0303 study［J］.Cancer Med,2018，7(7):3011-3021.
［21］ SUN Y,NIU W,DU F,et al.Safety,pharmacokinetics,and antitumor properties of anlotinib,an oral multi-target tyrosine kinase inhibitor,in patients with advanced refractory solid tumors［J］.J Hematol Oncol,2016,9(1):105.
［22］ HAN B,LI K,ZHAO Y,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer:a multicentre,randomized phase Ⅱ trial(ALTER0302)［J］.Br J Cancer,2018,118(5):654-661.
［23］ HAN B,LI K,WANG Q,et al.Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer:the ALTER 0303 phase 3 randomized clinical trial［J］.JAMA Oncol,2018,4(11):1569-1575.
［24］ WANG L,HE Z,YANG S,et al.The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer(NSCLC):a subgroup analysis of ALTER0303 trial［J］.Transl Lung Cancer Res,2019,8(5):575-583.
［25］ CHENG Y,HAN B,LI K,et al.Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types:subgroup analysis in the ALTER0303 trial［J］.Cancer Med,2020,9(8):2621-2630.
［26］ SHI J,CHEN G,WANG H,et al.Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer(SCC):a post hoc analysis of the ALTER0303 trial［J］.Thorac Cancer,2021,Online ahead of print.DOI:10.1111/1759-7714.14076.
［27］ JIANG S,LIANG H,LIU Z,et al.The impact of anlotinib on brain metastases of non-small cell lung cancer:post hoc analysis of a phase Ⅲ randomized control trial(ALTER0303)［J］.Oncologist,2020,25(5):e870-e874.
［28］ NAN X,XIE C,ZHU Q,et al.Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib:a subgroup analysis of data from the ALTER 0303 study［J］.Int J Clin Oncol,2020,25(8):1492-1498.
［29］ HAN B,CHU T,ZHANG X,et al.Efficacy and safety of anlotinib in combination with chemotherapy as first-line therapy in advanced non-small cell lung cancer(NSCLC) patients［J］.J Thorac Oncol,2019,14(10):S398.
［30］ HAN B,CHU T,SHI C,et al.Efficacy and safety of combing anlotinib and erlotinib as a first-line therapy in patients with advanced non-small cell lung cancer(NSCLC)［J］.J Thorac Oncol,2019,14(10):S646-S647.
［31］ HAN B,CHU T,ZHONG R,et al.Sintilimab in combination with anlotinib as first-line therapy for advanced NSCLC:final analysis of primary endpoints［J］.J Thorac Oncol,2021,16(3):S119.
［32］ HUANG M,LU Y,LIU M,et al.A phase I study of anlotinib combined with platinumpemetrexed in untreated non-squamous non-small cell lung cancer［J］.J Thorac Oncol,2021,16(3):S674.
［33］ FANG Y,PAN H,SHOU J,et al.Anlotinib plus docetaxel versus docetaxel as 2nd line treatment in advanced non-small cell lung cancer:a phase Ⅰ/Ⅱ study［J］.J Thorac Oncol,2021,16(3):S682.
［34］ CHEN X,SHEN J,LI X,et al.Anlotinib combination with doce-taxol for patients with previously treated advanced non-small cell lung cancer:a phase Ⅱ,single-arm trial［J］.Ann Oncol,2020,31(4 Suppl):S877.
［35］ WU L,WU Z,XIAO Z,et al.A randomized phase 2 trial of anlotinib plus docetaxel vs docetaxel as 2nd-line therapy for EGFR-negative NSCLC(ALTER-L018)［J］.J Thorac Oncol,2021,16(3):S596.
［36］ HUANG D,ZHONG D,ZHANG C,et al.Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer(NSCLC)patients harboring activating EGFR mutations(ALTER-L004)［J］.J Clin Oncol,2020,38(15 Suppl):9573.
［37］ ZHANG X,ZENG L,LI Y,et al.Anlotinib combined with PD-1 blockade for the treatment of lung cancer:a real-world retrospective study in China［J］.Cancer Immunol Immunother,2021,70(9):2517-2528.
［38］ CHENG Y,WANG Q,LI K,et al.Anlotinib as third-line or further-line treatment in relapsed SCLC:a multicentre,randomized,double-blind phase 2 trial［J］.J Thorac Oncol,2018,13(10):S351-S352.
［39］ LIU Y,CHENG Y,WANG Q,et al.Effect of anlotinib in advanced small cell lung cancer patients with pleural metastases/pleural effusion:a subgroup analysis from a randomized,double-blind phase Ⅱ trial(ALTER1202)［J］.Ann Oncol,2020,31(4 Suppl):S1036.
［40］ CHENG Y,WANG Q,LI K,et al.Effect of anlotinib in advanced small cell lung cancer(SCLC)patients with liver metastases:a subgroup analysis from a randomized,double-blind phase Ⅱ trial(ALTER 1202)［J］.Ann Oncol,2020,31(4):S1038.
［41］ WU D,NIE J,HU W,et al.A phase Ⅱ study of anlotinib in 45 patients with relapsed small cell lung cancer［J］.Int J Cancer,2020,147(12):3453-3460.
［42］ DENG P,YANG H,CHEN C,et al.The efficacy and safety profile of anlotinib with etoposide plus cisplatin/carboplatin in treatment-naive extensive-stage small cell lung cancer(SCLC)patients:results from a phase Ⅱ single-arm trial［J］.J Clin Oncol,2020,38(15):9066.DOI:10.1200/JCO.2020.38.15_suppl.9066.
［43］ SHEN B,WU Y,SHI L,et al.Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer(ES-SCLC):a single-arm,prospective phase Ⅱ study［J］.Ann Oncol,2020,31(4 Suppl):S1040.
［44］ KONG T,CHEN L,DUAN F,et al.Efficacy and safety analysis of EP/EC regimen combined with first-line anlotinib hydrochloride in the treatment of extensive small cell lung cancer:results from a phase Ⅱ single-arm trial［J］.Ann Oncol,2020,31(4 Suppl):S1040.
［45］ WANG H Y,CHU J F,ZHAO Y,et al.A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer［J］.Cancer Manag Res,2020,12:3827-3834.
［46］ GAO Y,LIU P,SHI R.Anlotinib as a molecular targeted therapy for tumors［J］.Oncol Lett,2020,20(2):1001-1014.
［47］ SI X,ZHANG L,WANG H,et al.Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer:experiences in ALTER-0303［J］.Thorac Cancer,2019,10(3):551-556.
［48］ ABDEL-RAHMAN O,FOUAD M.Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors:a critical literature review and meta analysis［J］.Expert Rev Anticancer Ther,2014,14(9):1063-1073.
［49］ SCHMIDINGER M.Understanding and managing toxicities of vascular endothelial growth factor(VEGF)inhibitors［J］.EJC Suppl,2013,11(2):172-191.
相似文献/References:
[1]杜华贞,和瑞芝,千高峰,等.肺癌痰液脱落细胞学检查——附164例分析[J].新乡医学院学报,1988,5(02):022.
[2]张彩平,范迎胜,李 新,等.肺癌患者医院真菌感染原因调查分析[J].新乡医学院学报,2002,19(05):416.
[3]朱自德.青年肺癌1O例临床分析[J].新乡医学院学报,2003,20(03):213.
[4]朱自德.青年肺癌10例临床分析[J].新乡医学院学报,2003,20(03):213.
[5]房秀清,尹丽欣,钞丽红.胸腔积液中癌胚抗原及CA125 和CA153 联合检测对肺癌的诊断意义[J].新乡医学院学报,2012,29(06):428.
[6]牛慧彦,王鑫,张萌,等.雷帕霉素联合多西紫杉醇对肺癌细胞增殖和凋亡的影响[J].新乡医学院学报,2012,29(01):000.
[7]孙 冰,杨亚勤,韩 伟,等.自发荧光支气管镜在肺癌早期诊断中的应用[J].新乡医学院学报,2013,30(03):223.
[8]姬颖华,杨晓煜,王 瑾,等.安罗替尼联合伊立替康方案二线治疗晚期复发难治性小细胞肺癌的临床疗效观察[J].新乡医学院学报,2021,38(4):328.[doi:10.7683/xxyxyxb.2021.04.006]
JI Yinghua,YANG Xiaoyu,WANG Jin,et al.Effect of anlotinib combined with irinotecan in the second-line treatment of advanced relapsed and refractory small cell lung cancer[J].Journal of Xinxiang Medical University,2021,38(10):328.[doi:10.7683/xxyxyxb.2021.04.006]
[9]屈亚云,武莉芳,张秀敏,等.依达拉奉对肺癌胸腔镜手术中单肺通气相关肺损伤的保护作用[J].新乡医学院学报,2016,33(12):1054.[doi:10.7683/xxyxyxb.2016.12.010]
QU Ya-yun,WU Li-fang,ZHANG Xiu-min,et al.Protective effect of edaravone on injury of lungs induced by one lung ventilation in lung cancer patients undergoing thorascopic surgery[J].Journal of Xinxiang Medical University,2016,33(10):1054.[doi:10.7683/xxyxyxb.2016.12.010]
[10]周 威,陈贡斌,刘海燕,等.黄芪甲苷对乌拉坦诱导肺癌小鼠的防治作用及其机制[J].新乡医学院学报,2021,38(1):018.[doi:10.7683/xxyxyxb.2021.01.004]
ZHOU Wei,CHEN Gongbin,LIU Haiyan,et al.Preventive and therapeutic effects of astragaloside IV on urethane induced lung cancer in mice and its mechanism[J].Journal of Xinxiang Medical University,2021,38(10):018.[doi:10.7683/xxyxyxb.2021.01.004]